IM Therapeutics is building an HLA-directed platform for new therapies. We have demonstrated early effectiveness in type 1 diabetes and are building a pipeline of targeted therapies across autoimmune diseases.
Our Approach
Our novel therapies are designed to specifically block the action of HLA proteins known to be involved in the trigger of autoimmune response.
News
October 5, 2021
IM Therapeutics to Present at the B & T Cell-Mediated Autoimmune Disease Drug Development Summit, October 5-7, 2021 | READ MORE
August 2, 2021
In the News: BioBoss Podcast, CEO Nandan Padukone discusses leadership and how IM Therapeutics is targeting the root cause of autoimmunity with therapeutics directed at human leukocyte antigens which are a window to the broader autoimmune spectrum | READ MORE
July 21, 2021
In the News: FierceBiotech, IM Therapeutics posts positive, early results for oral Type 1 diabetes hopeful | READ MORE
July 21, 2021
IM Therapeutics Reports Positive Results in Safety, Tolerability and Mechanism of Action of Phase 1b Trial of Lead Drug IMT-002 in Type 1 Diabetes | READ MORE
July 20, 2021
IM Therapeutics to Present at LifeSci Partners Summer Symposium on July 21, 2021 | READ MORE
June 24, 2021
IM Therapeutics Co-Founder and CMO Peter Gottlieb, M.D., to Present Advances in Genetically Targeted Therapies for Type 1 Diabetes at the 2021 ADA Scientific Sessions | READ MORE
June 1, 2021
Life Science Leader: Companies To Watch: IM Therapeutics | READ MORE
April 23, 2021
European Pharmaceutical Review: A new small molecule drug discovery and development platform for HLA-associated autoimmune diseases | READ MORE
April 6, 2021
IM Therapeutics Expands Management Team with David Alleva, Ph.D. as VP, Immunology | READ MORE
January 27, 2021
IM Therapeutics Announces Appointment of Jonathan Rigby to Board of Directors | READ MORE